Komplikationen nach pleuralem getunnelten Dauerkatheter bei symptomatischen rezidivierenden benignen und malignen Pleuraergüssen

Zusammenfassung

Einleitung Die Implantation eines pleuralen getunnelten Dauerkatheters (indwelling pleural catheter = IPC) stellt bei symptomatischen rezidivierenden benignen und malignen Pleuraergüssen (BPE und MPE) neben einer Pleurodese eine weitere etablierte Therapiemethode dar.

Zur Sicherheit des IPC, insbesondere zu Pneumothorax und Katheterinfektionen, existierten wenige Studien.

Ziel unserer Untersuchung war, die Komplikationshäufigkeit nach IPC-Anlage und deren prädiktive Faktoren bei Patienten mit BPE vs. MPE zu ermitteln.

Methoden Retrospektive Analyse aller IPC-Implantationen im Bereich Pneumologie am Universitätsklinikum Dresden im Zeitraum von 2015 – 2018.

Ergebnisse Bei 86 Patienten (je 43 m/f; Alter 66,9 ± 13,3 Jahre) wurde bei symptomatischem BPE und MPE ein IPC implantiert. Ein BPE bzw. MPE bestand bei 12,8 % (11/86) bzw. 87,2 % (75/86) der Erkrankten.

Als Sofortkomplikation nach IPC-Anlage war bei 43/86 (50 %) Patienten ein meist kleiner, asymptomatischer Pneumothorax nachweisbar. 34/43 (79 %) Patienten bedurften diesbezüglich keiner spezifischen Therapie. Bei 9/43 war ein IPC-Sog im Median über 3 Tage erforderlich. 8/43 Patienten wiesen einen großen Pneumothorax mit partieller/kompletter Regredienz im Median nach 2 Tagen auf.

Bei 15,1 % (13/86) der Gesamtgruppe und 36,4 % (4/11) der BPE vs. 12 % (9/75) der MPE kam es im Median nach 87 (BPE/MPE 116/87) Tagen zu einer Katheterinfektion. Diese war bei BPE (p = 0,035), großem Pneumothorax (4/8 Patienten; p = 0,015) und längerer Katheterverweildauer (124 ± 112 vs. 71 ± 112 Tage; p = 0,07) häufiger.

Schlussfolgerung Kleine Pneumothoraces sind häufig nach IPC-Implantation, bedürfen aber meist keiner spezifischen Therapie. Bei 15,1 % aller Patienten war im Median nach 87 Tagen eine Katheterinfektion nachweisbar. Diese trat häufiger bei BPE, längerer Katheterverweildauer und großen Pneumothoraces auf.

Abstract

Background Implant of indwelling pleural catheters (IPC) represents an established therapy method in addition to pleurodesis for symptomatic recurrent benign and malignant pleural effusions (BPE and MPE).

There are only few studies on IPC safety during follow-up, especially with regard to infection and pneumothorax rates.

The aim of our investigation was to determine the complication frequency after IPC implant and its predictive factors in patients with BPE vs. MPE.

Methods Retrospective analysis of all IPC implantations in the pneumology department at the University Hospital Dresden during 2015 – 2018.

Results An IPC was implanted in 86 patients (43 m/f each; age 66.9 ± 13.3 years) with symptomatic BPE and MPE. BPE and MPE was present in 12.8 % (11/86) and 87.2 % (75/86) of the patients, respectively.

A predominantly small and asymptomatic pneumothorax was detectable as an immediate complication in 43/86 (50 %) of patients; 34/43 (79 %) of patients did not require any specific therapy. For 9/43 patients, IPC suction was required for a median period of three days; 8/43 patients had a large pneumothorax with partial or complete regression after a median period of two days.

Catheter infection developed in 15.1 % (13/86) of the total group and 36.4 % (4/11) of the BPE vs. 12 % (9/75) of the MPE after a median period of 87 (BPE/MPE 116/87) days. This was more common in BPE (p = 0.035), large pneumothorax (4/8 patients; p = 0.015) and longer catheter dwell times (124 ± 112 vs. 71 ± 112 days; p = 0.07).

Conclusion Small pneumothoraxes are frequent after IPC implantation, but usually do not require specific therapy. IPC infection was detected in 15.1 % of all patients after a median period of 87 days. This was more common in patients with BPE, longer catheter dwell times and large pneumothorax.

Publication History

Received: 20 April 2020

Accepted: 16 June 2020

Article published online:
14 July 2020

• Literatur

• 1 Bibby AC, Dorn P, Psallidas I. et al. ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 2018; DOI: 10.1183/13993003.00349-2018.
• 2 Bramley K, Debiasi E, Puchalski J. Indwelling Pleural Catheter Placement for Nonmalignant Pleural Effusions. Semin Respir Crit Care Med 2018; DOI: 10.1055/s-0038-1676648.
• 3 Patil M, Dhillon SS, Attwood K. et al. Management of Benign Pleural Effusions Using Indwelling Pleural Catheters: A Systematic Review and Meta-analysis. Chest 2017; 151: 626-635
• 4 Aboudara M, Maldonado F. Indwelling pleural catheters for benign pleural effusions: What is the evidence?. Curr Opin Pulm Med 2019; 25: 369-373
• 5 WMA. WMA Delcaration of Helsinki – Ethical principles for medical research involving human subjects. 64th WMA Gen Assem Fortaleza, Brazil; 2013 DOI: 10.1001/jama.2013.281053
• 6 Putnam JB, Light RW, Rodriguez RM. et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 1999; 86: 1992-1999
• 7 Collins CD, Lopez A, Mathie A. et al. Quantification of pneumothorax size on chest radiographs using interpleural distances: Regression analysis based on volume measurements from helical CT. Am J Roentgenol 1995; 165: 1127-1130
• 8 Ferguson K, Blyth K, Tsim S. IPC-related pleural infection vs. colonisation – to treat or not to treat?. 2019; DOI: 10.1183/13993003.congress-2019.pa3836.
• 9 Rahman NM, Maskell NA, West A. et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365: 518-526
• 10 Abrão FC, Abreu IRLB de, Cavalcanti MG. et al. Use of indwelling pleural catheters for the definitive treatment of malignant pleural effusion. J Bras Pneumol 2017; 43: 14-17
• 11 Lücke E, Steffen U, Riedel S. et al. Effektivität und Sicherheit von getunnelten pleuralen Dauerkathetern. Zentralblatt für Chir – Zeitschrift für Allg Visz Thorax- und Gefäßchirurgie 2018; 143: 290-295
• 12 Raman T, Meena N. A single institution experience for the management of recurrent pleural effusions with tunneled pleural catheter and its evolution. Ther Adv Respir Dis 2017; 11: 343-352
• 13 Frost N, Ruwwe-Glösenkamp C, Raspe M. et al. Indwelling pleural catheters for non-malignant pleural effusions: Report on a single centre’s 10 years of experience. BMJ Open Respir Res 2020; DOI: 10.1136/bmjresp-2019-000501.
• 14 Frost N, Brünger M, Ruwwe-Glösenkamp C. et al. Indwelling pleural catheters for malignancy-associated pleural effusion: Report on a single centre’s ten years of experience. BMC Pulm Med 2019; DOI: 10.1186/s12890-019-1002-8.
• 15 Chalhoub M, Saqib A, Castellano M. Indwelling pleural catheters: Complications and management strategies. J Thorac Dis 2018; 10: 4659-4666
• 16 Faiz SA, Pathania P, Song J. et al. Indwelling pleural catheters for patients with hematologic malignancies a 14-year, single-center experience. Ann Am Thorac Soc 2017; 14: 976-985
• 17 Gilbert CR, Lee HJ, Skalski JH. et al. The use of indwelling tunneled pleural catheters for recurrent pleural effusions in patients with hematologic malignancies: A multicenter study. Chest 2015; 148: 752-758
• 18 Kniese C, Diab K, Ghabril M. et al. Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications. Chest 2019; 155: 307-314
• 19 Shojaee S, Rahman N, Haas K. et al. Indwelling Tunneled Pleural Catheters for Refractory Hepatic Hydrothorax in Patients With Cirrhosis: A Multicenter Study. Chest 2019; 155: 546-553
• 20 Fysh ETH, Tremblay A, Feller-Kopman D. et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: An international multicenter study. Chest 2013; 144: 1597-1602
• 21 Thomas R, Piccolo F, Miller D. et al. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: A multicenter observational study. Chest 2015; 148: 746-751
• 22 Lan NSH, Vekaria S, Sidhu C. et al. Very low-dose intrapleural tPA for indwelling pleural catheter-associated symptomatic fluid loculation. Respirol Case Reports 2019; DOI: 10.1002/rcr2.457.
• 23 Fitzgerald D, Muruganandan S, Uribe-Becerra JP. et al. Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection. Eur Respir J 2019; 54: PA3835 DOI: 10.1183/13993003.congress-2019.pa3835.
• 24 Dilkaute M, Klapdor B, Scherff A. et al. PleurX drainage catheter for palliative treatment of malignant pleural effusion. Pneumologie 2012; 66: 637-644
• 25 Andreu M, Sola R, Sitges-Serra A. et al. Risk factors for spontaneous bacterial peritonitis in cirrhotic patients with ascites. Gastroenterol 1993; 104: 1133-1138